Soft Tissue Sarcoma Market Overview

The global soft tissue sarcoma market size was valued at USD 3,321.6 million in 2024 and is projected to grow from USD 3,501.6 million in 2025 to USD 5,343.0 million by 2032, exhibiting a CAGR of 6.22% during the forecast period.

This growth is driven by the rising global incidence of soft tissue sarcoma, prompting greater focus on targeted and effective treatment options due to limited therapies and high recurrence rates. Additionally, collaborations between biotech firms and large pharmaceutical companies are streamlining clinical development and commercialization, further supporting market expansion.

Key Market Highlights:

The soft tissue sarcoma industry size was valued at USD 3,321.6 million in 2024.
The market is projected to grow at a CAGR of 6.22% from 2025 to 2032.
North America held a market share of 36.52% in 2024, with a valuation of USD 1,213.0 million.
The local sarcoma segment garnered USD 1,317.3 million in revenue in 2024.
The surgery segment is expected to reach USD 1,719.5 million by 2032.
The parenteral segment is anticipated to witness the fastest CAGR of 6.29% over the forecast period.
Asia Pacific is anticipated to grow at a CAGR of 7.12% through the projection period.

Major companies operating in the soft tissue sarcoma market are Advenchen Laboratories LLC, Philogen S.p.A., Gradalis, Inc., Chugai Pharmaceutical Co., Ltd, Bayer, Novartis AG, Bristol-Myers Squibb Company, AstraZeneca, GSK plc, Salarius Pharmaceuticals, Inc., Telix Pharmaceuticals Limited, Sun Pharmaceutical Industries Ltd, Aurobindo Pharma Limited and Nanobiotix.

Additionally, growing research and development funding is accelerating innovation in soft tissue sarcoma treatment which are supporting novel drug discovery, enhancing clinical trials, and fostering collaborations to support faster advancement of targeted therapeutic solutions.

In 2024, the Sarcoma Foundation awarded USD 800,000 in research grants to selected researchers and institutions focused on advanced sarcoma research. This funding is expected to enable clinical trials and the development of novel treatments, fueling the market growth.

Market Driver

Increasing Incidence of Soft Tissue Sarcoma

The increase in soft tissue sarcoma cases is significantly influencing the soft tissue sarcoma market growth, as the rising number of diagnoses continues to boost demand for effective treatment options. Soft tissue sarcoma is a rare and heterogeneous group of cancers that originate in the connective tissues of the body, including muscles, fat, nerves, blood vessels, and deep skin tissues.

Improved diagnostic technologies and greater clinical awareness are contributing to the steady rise in identified cases. In response, healthcare systems are investing in early detection infrastructure and advanced therapeutic strategies.

Pharmaceutical companies are also intensifying research to develop targeted therapies, t argeting critical therapeutic gaps and driving market expansion.

In 2025, The American Cancer Society estimates 13,520 new cases of soft tissue sarcomas in the U.S. with 7,600 in males and 5,920 in females. The rising caseload is driving demand for timely diagnosis and effective treatment solutions, contributing to market growth.

Market Challenge

High Treatment Costs of Surgery

The high treatment costs of soft tissue sarcoma surgery present a significant challenge to the market, limiting accessibility for many patients. These surgery treatments require prolonged administration, specialized facilities, and continuous monitoring, adding to the overall financial burden.

Limited reimbursement policies and inadequate insurance coverage in several regions further restrict patient access. The economic burden of soft tissue sarcoma is particularly significant in low- and middle-income countries, where underdeveloped healthcare infrastructure and limited funding hinder access to timely diagnosis, advanced treatments, and consistent care.

To address high treatment costs, companies are adopting strategies such as tiered pricing models and expanding patient assistance programs to improve affordability. Partnerships with government bodies and non-profit organizations are supporting access in low-resource settings.

Additionally, firms are investing in the development of biosimilar and cost-effective oral therapies to reduce treatment expenses. They are also working to streamline clinical trial designs and leverage real-world data to accelerate approvals, potentially lowering research and development costs and overall drug prices.

Market Trend

Advancing Immunotherapy for Pediatric and AYA Sarcoma

Advancing immunotherapy for pediatric and adolescents and young adults (AYA) is shaping a transformative shift in the soft tissue sarcoma market. The growing focus on age-specific treatment approaches is adopting the development of immune checkpoint inhibitors and targeted therapies aimed at rare, aggressive tumor types in younger patients.

These approaches are demonstrating improved clinical outcomes in sarcoma subtypes that show limited response to conventional treatment options.

Increased regulatory support for pediatric trials, along with improved understanding of tumor behavior in adolescent and young adult groups, is driving progress in developing more targeted, reliable, and safer treatment approaches.

In February 2025, Chugai Pharmaceutical received regulatory approval in Japan for Tecentriq (atezolizumab) as the first immune checkpoint inhibitor for unresectable alveolar soft part sarcoma in adults and children over two years old. The approval is based on phase II clinical studies conducted in Japan and the U.S., targeting a rare sarcoma subtype with no established standard treatment.

Soft Tissue Sarcoma Market Report Snapshot

Segmentation	Details
By Disease Type	Local Sarcoma, Regional Sarcoma, Metastatic Sarcoma, Others
By Treatment Type	Surgery, Radiation Therapy, Chemotherapy, Immunotherapy, Others
By Route of Administration	Oral, Parenteral
By Region	North America: U.S., Canada, Mexico
	Europe: France, UK, Spain, Germany, Italy, Russia, Rest of Europe
	Asia-Pacific: China, Japan, India, Australia, ASEAN, South Korea, Rest of Asia-Pacific
	Middle East & Africa: Turkey, U.A.E., Saudi Arabia, South Africa, Rest of Middle East & Africa
	South America: Brazil, Argentina, Rest of South America

Market Segmentation:

By Disease Type (Local Sarcoma, Regional Sarcoma, Metastatic Sarcoma and Others): The local sarcoma segment earned USD 1,317.3 million in 2024 due to early diagnosis and higher treatment success rates.
By Treatment Type (Surgery, Radiation Therapy, Chemotherapy, and Immunotherapy): The surgery segment held 36.33% of the market in 2024, due to its effectiveness in removing localized tumors and reducing recurrence.
By Route of Administration (Oral and Parenteral): The parenteral segment is projected to reach USD 3,166.7 million by 2032, owing to its rapid absorption and suitability for advanced-stage therapies.

Soft Tissue Sarcoma Market Regional Analysis

Based on region, the global market has been classified into North America, Europe, Asia Pacific, Middle East & Africa, and South America.

Soft Tissue Sarcoma Market Size & Share, By Region, 2025-2032

North America soft tissue sarcoma market accounted for a share of 36.52% in 2024. with a valuation of USD 1,213.0 million. This dominance is attributed to the region’s strong clinical focus on rare cancer treatment and the availability of advanced healthcare infrastructure.

The North American market is witnessing increased pharmaceutical investment in targeted biologics and immunotherapies as stakeholders prioritize more effective and durable treatment options for soft tissue sarcoma.

Moreover, the region is seeing sustained efforts in early diagnosis, precision medicine, and clinical trial expansion aimed at improving treatment access and outcomes. Leading oncology institutions are also enhancing the region’s research capabilities, accelerating the development and adoption of advanced therapies, and further strengthening market expansion in the region.

According to the National Cancer Institute, the U.S. age-adjusted mortality rate is 1.3 deaths per 100,000 people annually (2019–2023), with approximately 5,410 deaths from STS expected in 2025.

The Asia Pacific soft tissue sarcoma industry is set to grow at a robust CAGR of 7.12% over the forecast period. This growth is driven by increasing efforts to expand access to advanced cancer therapies, supported by rising pharmaceutical investment in biologic innovation and translational oncology research.

Market players in the region are forming strategic licensing agreements and cross-border partnerships to accelerate the development and commercialization of late-stage immunotherapies for rare and aggressive cancers.

These collaborations are streamlining clinical development processes and facilitating regulatory approvals, allowing faster market entry of promising drug candidates.

Additionally, improvements in oncology manufacturing infrastructure are enhancing scalability and ensuring consistent treatment availability across the region. This is strengthening the regional capacity to support advanced therapeutic delivery and contributing to market growth in the region.

In October 2024, Sun Pharmaceutical Industries entered an exclusive global licensing agreement with Philogen S.p.A to commercialize Fibromun (L19TNF), an immunotherapy in late-stage trials for soft tissue sarcoma and glioblastoma. Under the deal, Philogen will manage clinical development and manufacturing and Sun Pharma will oversee global commercialization.

Regulatory Frameworks

In the U.S., Food and Drug Administration (FDA) regulates the market by overseeing the approval, safety, and efficacy of drugs and biologics. Through its Oncology Center of Excellence, the FDA provides fast-track designations, orphan drug status, and accelerated approvals for innovative cancer therapies, supporting faster market entry and wider patient access.
In China, the National Medical Products Administration (NMPA) regulates oncology drugs in China, including those for soft tissue sarcoma, by managing clinical trial approvals, product registrations, and quality standards.
In India, the Central Drugs Standard Control Organization (CDSCO) regulates the market by evaluating clinical trials, drug approvals, and post-market surveillance. It monitors safety and efficacy while promoting faster access through its accelerated approval pathways for rare diseases.
In the UK, the Medicines and Healthcare Products Regulatory Agency (MHRA) oversees the regulation of oncology treatments, including soft tissue sarcoma, by reviewing clinical trial applications, licensing medicines, and monitoring drug safety.

Competitive Landscape

Major players in the soft tissue sarcoma market are forming strategic acquisitions to expand access to precision therapies targeting rare cancer subtypes. They are integrating advanced molecules, such as selective KIT tyrosine kinase inhibitors, into their pipelines to address both primary and secondary mutations in gastrointestinal stromal tumors.

Market players are developing therapies with broader mutation coverage to improve treatment durability and reduce resistance. Additionally, they are accelerating clinical development timelines to bring next-generation oncology solutions to market more efficiently and expand their therapeutic reach.

In January 2025, GSK acquired IDRx, Inc., a clinical-stage biopharmaceutical company developing precision therapies for gastrointestinal stromal tumors (GIST), the most common subtype of soft tissue sarcoma. The deal, valued at up to USD 1.15 billion, includes IDRX-42, a highly selective KIT tyrosine kinase inhibitor designed to target both primary and secondary KIT mutations.

Key Companies in Soft Tissue Sarcoma Market:

Advenchen Laboratories LLC
Philogen S.p.A.
Gradalis, Inc.
Chugai Pharmaceutical Co., Ltd
Bayer
Novartis AG
Bristol-Myers Squibb Company
AstraZeneca
GSK plc
Salarius Pharmaceuticals, Inc.
Telix Pharmaceuticals Limited
Sun Pharmaceutical Industries Ltd
Aurobindo Pharma Limited
Nanobiotix

Recent Developments

In September 2024, Actuate Therapeutics received Orphan Drug Designation from the U.S. FDA for elraglusib in the treatment of advanced soft tissue sarcoma. This supports the company’s ongoing efforts to develop elraglusib as part of combination regimens for patients with unresectable or metastatic disease, targeting a critical therapeutic gap in this rare cancer subtype.

the